Loading
Life sciences · Journal article
Molecular Therapy — Nucleic Acids · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is projected to affect 38% of adults and is now the leading cause of chronic liver disease worldwide.1 MASLD spans a continuum from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), which can progress to cirrhosis and hepatocellular carcinoma (HCC). The only FDA-approved therapies for patients with MASH and moderate-to-advanced fibrosis are semaglutide and resmetirom, an oral, liver-directed, thyroid hormone receptor β (THR-β)-selective agonist.